The extracellular signal-regulated kinase (ERK) signaling pathway is constitutively activated in many human tumor cell types. Given the cytoprotective role of this pathway, we examined whether its specific blockade might sensitize human tumor cells to the induction of apoptosis by various anticancer drugs. Although blockade of ERK signaling alone did not induce substantial cell death, it resulted in marked and selective enhancement of the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the ERK pathway is constitutively activated. The synergistic activation of c-Jun NH 2 -terminal kinase by the combination of an ERK pathway inhibitor and a microtubule-destabilizing agent appeared to be responsible, at least in part, for this effect.
Introduction
The extracellular signal-regulated kinase (ERK) pathway is activated in a variety of cell types by diverse extracellular stimuli and is among the most extensively studied of signaling pathways that connect various membrane receptors to the nucleus [1, 2] .
Activation of the ERK pathway is triggered by GTP loading of Ras at the plasma membrane, which is followed by sequential activation of a series of protein kinases including a member of the Raf family (such as Raf-1), mitogen-activated protein (MAP) kinase or ERK kinase (MEK) 1 and 2, and ERK1 and ERK2. Activated ERK1/2 then phosphorylates various downstream substrates that contribute to the regulation of a wide range of cellular processes such as proliferation, differentiation, survival, and motility.
Mechanisms for precise spatiotemporal control of intracellular signaling pathways have evolved to ensure homeostasis in multicellular organisms. Inappropriate activation of these pathways underlies several refractory diseases, with aberrant activation of the ERK pathway having been shown to be a key contributing factor to many types of human cancer [3, 4] . In particular, overexpression or activating mutation of the epidermal growth factor receptor (EGFR) gene (in tumors of the lung, breast, colon, ovary, and bladder) [5] , activating mutation of RAS (in tumors of the pancreas, colon, and lung) [6] , and activating mutation of RAF (in melanomas and tumors of the colon, ovary, and thyroid) [7] have been associated with cancer and found to result in the activation of MEK1/2 and ERK1/2 in most cases. Inhibition of the ERK pathway thus represents a promising strategy for cancer treatment [8, 9] .
We have previously shown that specific blockade of the ERK pathway by MEK inhibitors results in marked suppression not only of the proliferation [10] but also of the invasiveness [11] of tumor cells in which the pathway is constitutively activated.
However, blockade of the ERK pathway by itself was found to be largely cytostatic, rather than cytotoxic, resulting in only a moderate induction of apoptosis in these tumor cells [10] . Efficient induction of apoptotic cell death is essential for the development of effective cancer chemotherapy [9] .
Combination therapy based on cytotoxic agents with nonoverlapping toxicities is a key approach to cancer treatment, being generally driven by safety considerations.
Interruption of the cytoprotective ERK pathway by MEK inhibitors has thus been proposed as a means to enhance the action of cytotoxic anticancer agents [12] .
Consistent with this notion, the chemotherapeutic effects of doxorubicin and paclitaxel were found to be enhanced by the MEK inhibitor U0126 in H460 human non-small cell lung cancer cells [13] . We have also recently shown that the MEK inhibitor PD184352 enhances the induction of apoptosis by histone deacetylase inhibitors in a variety of tumor cells with constitutive activation of the ERK pathway [14] .
We now show that blockade of the ERK pathway results in marked enhancement of the cytotoxic effect of microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. The combination of an ERK pathway inhibitor with a microtubule-destabilizing drug induced synergistic activation of c-Jun NH 2 -terminal kinase (JNK), with this effect appearing to be responsible, at least in part, for the enhanced induction of cell death.
Materials and Methods
Materials. Vincristine, paclitaxel, and cytosine β-D-arabinofuranoside (Ara-C) were obtained from Sigma; etoposide (VP-16), cisplatin, and doxorubicin were from Wako (Osaka, Japan); and SP600125 was from Biomol. PD184352 were synthesized as described previously [11] . TZT-1027 and vinorelbine were kindly provided by Teikoku Hormone (Kawasaki, Japan). Antibodies to ERK1/2 and to EGFR were from Santa Cruz Biotechnology; those to diphosphorylated ERK1/2, to Tyr Eagle's medium supplemented with 10% fetal bovine serum [4] . Cells exposed to various reagents were harvested by treatment with trypsin, fixed with 70% ethanol, treated with DNase-free RNase A (100 µg/ml, Sigma), stained with propidium iodide (20 µg/ml), and analyzed for DNA content with the use of a FACSCalibur flow cytometer and Cell Quest Pro software (Becton Dickinson) [10] .
Immunoblot analysis. Cell lysates were prepared as described previously [10, 11] and fractionated by SDS-polyacrylamide gel electrophoresis, and the separated proteins were transferred to a polyvinylidene difluoride membrane and probed with primary antibodies and horseradish peroxidase-conjugated secondary antibodies (Promega).
Immune complexes were visualized with enhanced chemiluminescence reagents (GE Healthcare Bio-Sciences). 
RNA interference. The sequences 5′-GGGCCTACAGAGAGCTAGTTCTTAT-3′
and 5′-CCAACTGTGAGGAATTATGTCGAAA-3′ were designed to generate small interfering RNA (siRNA) duplexes specific for human JNK1 and JNK2 mRNAs, respectively; the scrambled oligoribonucleotide 5′-GGGATACAGAGCGATTGCTTCCTAT-3′ was used as a control (Invitrogen).
Subconfluent cultures of T24 cells were transfected with siRNA (50 nM) for 48 h with the use of the LipofectAMINE 2000 reagent (Invitrogen).
Results and Discussion

Blockade of the ERK pathway sensitizes tumor cells to the induction of cell death by
microtubule-destabilizing agents. We have previously shown that specific blockade of the ERK pathway by MEK inhibitors such as PD98059 and PD184352 completely suppresses the growth of tumor cells in which the pathway is constitutively activated.
However, blockade of the ERK pathway by itself resulted in only a moderate induction of cell death in these tumor cells [10] . Thus, although treatment of T24 cells with PD98059
(50 µM) or PD184352 (10 µM) totally suppressed the activation of ERK1/2 as well as cell proliferation (Fig. 1A) , it did not increase the proportion of dead cells with a fractional DNA content (cells in sub-G 1 phase) (Fig. 1B) , which is a characteristic feature of apoptotic cell death [16] . Furthermore, the MEK inhibitor-induced suppression of cell growth was reversible, with cells resuming proliferation after removal of the inhibitor (Fig.   1A ). Induction of cell death is essential for the development of effective cancer chemotherapy.
To provide a basis for the development of new chemotherapeutic strategies against cancer, we examined whether specific blockade of the ERK pathway might sensitize tumor cells to the cytotoxic action of chemotherapeutic agents by promoting cell death.
Each of the anticancer drugs examined (Ara-C, VP-16, cisplatin, doxorubicin, vincristine, and paclitaxel) induced the death of T24 and HT1080 cells, with the proportion of cells in sub-G 1 phase increasing to between 40 and 80% after treatment with optimal drug 8 concentrations for more than 48 h (Fig. 1D , data not shown). To examine the effect of ERK pathway inhibition on death induction by these anticancer drugs, we therefore treated the tumor cells with suboptimal drug concentrations that increased the proportion of cells in sub-G 1 phase to ~20% after 48 h (Fig. 1B, C) .
PD98059 markedly enhanced the induction of cell death by vincristine in both T24
and HT1080 cells (Fig. 1B, C) . This effect of PD98059 on death induction by vincristine was most pronounced at low concentrations of the latter drug in T24 (≤3 nM) and PC-9
(≤10 nM) cells; under such conditions, vincristine by itself exhibited only a small cytotoxic effect in these cells (Fig. 1D ). In contrast, the effect of PD98059 on the cytotoxicity of Ara-C, VP-16, cisplatin, or doxorubicin was suppressive or differed between tumor cell lines (Fig. 1C) . Although PD98059 potentiated the induction of cell death by paclitaxel in these tumor cells [17] , the effect was less pronounced than that observed with vincristine (Fig. 1C) . In subsequent experiments, we therefore focused on the effect of ERK pathway inhibition on the induction of cell death by microtubule-destabilizing agents. including vincristine, vinorelbine, and TZT-1027 [18] . Furthermore, treatment of II-18 cells with gefitinib, a potent EGFR tyrosine kinase inhibitor [19] , abolished the autophosphorylation of EGFR as well as markedly inhibited ERK1/2 activation and enhanced the induction of cell death by vincristine (Fig. 2C) . Together, these results indicated that blockade of the ERK pathway not only by a MEK inhibitor (directly) but also by an EGFR inhibitor (indirectly) sensitizes tumor cells to the induction of cell death by microtubule-destabilizing agents. and those expressing the activated form of caspase-3 (Fig. 3A) , all of which are characteristics of the early phase of apoptotic cell death [20] . Immunoblot analysis also revealed that the drug combination induced the cleavage (activation) of caspase-3 to yield 19-and 17-kDa fragments (Fig. 3B) . These results thus indicate that apoptosis is the major mechanism of cell death induced by the combination of PD98059 and a low concentration of vincristine in T24 cells.
The combination of an ERK pathway inhibitor and a low concentration of microtubule-destabilizing agent induces apoptosis mediated in part by
The net balance of signaling by the cytoprotective ERK1/2 pathway and the stress-related JNK1/2 and p38 MAP kinase pathways has been suggested to determine whether cells survive or undergo apoptotic cell death on exposure to various insults [21] .
To investigate the molecular mechanism by which MEK inhibitors enhance the induction of apoptosis by vincristine, we examined the activation status of these kinases in T24 cells exposed to PD98059, 3 nM vincristine, or the combination of these agents. Although vincristine alone, but not PD98059, induced the activation of JNK, the extent of vincristine-induced JNK activation was greatly increased by the presence of the MEK inhibitor (Fig. 3B) . Furthermore, the addition of 10 µM SP600125, a specific inhibitor of JNK [22] , suppressed the induction of cell death by the combination of vincristine and PD98059 (Fig. 3C) . 
